| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_563c667842ce95888b891b6c7b99dca6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6043 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2018-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32a16074441a507de69d27d2ac700896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ac91601be28523e0ce9b22a778cf0c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9bc27817d43b5995b0ca071c1e0bd2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_349d90604b31e19262df86dfb0cb663b |
| publicationDate |
2019-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019129315-A1 |
| titleOfInvention |
Pharmaceutical composition comprising an apl peptide |
| abstract |
The invention relates to a pharmaceutical composition comprising the APL peptide of SEQ ID No. 1, the sodium acetate buffer with a pH of 3.9-4.7, and at least one stabilising sugar selected from saccharose and trehalose. This pharmaceutical composition is useful for the treatment of inflammatory diseases associated with an increase of neutrophils or protein citrullination. These inflammatory diseases include rheumatoid arthritis (RA), juvenile chronic arthritis (JCA), ankylosing spondylitis (AS), Alzheimer's disease and hepatic or pulmonary fibrosis. The invention also relates to a method for the treatment of these diseases by administration of a therapeutically effective dose of the pharmaceutical composition of the APL peptide of SEQ ID No. 1. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021209080-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021129897-A1 |
| priorityDate |
2017-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |